Patents by Inventor Susanna Mandruzzato

Susanna Mandruzzato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of myeloid cell biomarkers for the diagnosis of cancer
    Patent number: 9671404
    Abstract: The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: June 6, 2017
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Harpreet Singh, Regina Mendrzyk, Steffan Walter, Vincezq Bronte, Susanna Mandruzzato
  • MYELOID-DERIVED SUPPRESSOR CELLS GENERATED IN VITRO
    Publication number: 20120225038
    Abstract: A population of myeloid-derived suppressor cells and the culture procedure to obtain these in vitro starting with bone marrow cells of mice, other animals and human beings, in the presence of specific cytokine combinations used to determine concentrations, is provided.
    Type: Application
    Filed: January 28, 2009
    Publication date: September 6, 2012
    Applicant: Istituto Oncologico Veneto
    Inventors: Vincenzo Bronte, Susanna Mandruzzato
  • USE OF MYELOID CELL BIOMARKERS FOR THE DIAGNOSIS OF CANCER
    Publication number: 20120070461
    Abstract: The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.
    Type: Application
    Filed: September 21, 2011
    Publication date: March 22, 2012
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Harpreet SINGH, Regina MENDRZYK, Steffen WALTER, Vincenzo BRONTE, Susanna MANDRUZZATO
  • Nucleic acid molecule encoding a bifunctional protein, the protein so encoded uses thereof
    Patent number: 5955313
    Abstract: The invention involves the identification of an isolated nucleic acid molecule which encodes a tumor rejection antigen. Various uses of this nucleic acid molecule and the protein it encodes are discussed.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: September 21, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Susanna Mandruzzato, Thierry Boon-Falleur
  • Isolated cytolytic T cells which are specific for complexes OF HLA- B35 molecules and the peptide PHE Pro Ser Asp Ser Trp Cys Tyr PHE, and uses thereof
    Patent number: 5952228
    Abstract: The invention relates to isolated cytolytic T cells which recognize complexes of HLA-B35 molecules and the peptide defined by SEQ ID NO: 2, as well as methods for identifying HLA-B35 positive cells. The method involves contacting the cytolytic T cells to a sample, and determining activity of these cytolytic T cells.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: September 14, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Susanna Mandruzzato, Thierry Boon-Falleur
  • Nucleic acid molecule encoding a bifunctional protein, the protein so encoded and uses thereof
    Patent number: 5932694
    Abstract: The invention involves the identification of an isolated nucleic acid molecule which encodes a tumor rejection antigen. Various uses of this nucleic acid molecule and the protein it encodes are discussed.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: August 3, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Susanna Mandruzzato, Thierry Boon-Falleur